ClinicalTrials.gg
CompletedNCT01625377SIMCERUpdated Apr 27, 2016Results posted

A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients

A Phase 3 interventional study of tacrolimus and everolimus in Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aims of the study was to evaluate the safety and efficacy of early introduction one month post-transplantation of everolimus associated to EC-MPS with tacrolimus discontinuation in de novo liver transplant recipients and to evaluate if it leads to a better renal function 6 month post-transplantation compared to standard treatment associating tacrolimus and EC-MPS.

The renal function was estimated by glomerular filtration rate.

02

Conditions studied

  • Liver Transplantation

Keywords

  • Everolimus,
  • liver transplantation,
  • early introduction,
  • renal function
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Man or woman aged 18 years or greater, recipient of a primary liver transplant from a deceased donor with whole or split liver

Key Exclusion Criteria:

  • Patient recipient of multiple solid organ or islet cell tissue transplants, or have previously received an organ or tissue transplant
  • Recipient of a liver from a living donor or cadaveric non heart beating donor
  • ABO incompatible transplant graft
  • Transplantation following liver hepatitis, primitive sclerosing cholangitis or primitive biliary cirrhosis
  • Estimated ≤ 30ml/min at selection
  • History of within the 5 past years, other than non- basal or squamous cell carcinoma and hepatocellular carcinoma
  • Alpha-foeto-protein > 1000 ng/ml (only in case of hepatocellular carcinoma)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
188 participants (actual)

Study arms

  • Active comparator
    Tacrolimus

    From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids

    Drug: tacrolimus · Drug: Basiliximab · Drug: Mycophenolic Acid · Drug: Corticosteroids

  • Experimental
    Everolimus (RAD001)

    From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest).

    Drug: tacrolimus · Drug: everolimus · Drug: Basiliximab · Drug: Mycophenolic Acid · Drug: Corticosteroids

Interventions

  • Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.

    Also known as: Prograf®

  • Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation

    Also known as: Certican® / RAD001

  • Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4

    Also known as: Simulect®

  • Dose of 1440 mg/day from transplantation to month 6 post- transplantation

    Also known as: Myfortic®

  • DrugCorticosteroids

    Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice

06

What researchers measure

Primary outcomes

  1. Change From Baseline (Randomization) in Renal Function

    Change in renal function was measured by change in glomerular filtration rate (GFR). GFR calculated using the abbreviated modification of diet in renal disease (aMDRD) formula. GFR in mL/min/1.73m\^2 for men of non-black ethnicity: 186 \* \[C/88\]\^-1.154 \* \[A\]\^-0.023\*G\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Number of Patients With Treatment Failures

    Incidence of treatment failures, assessed with composite criterion including treated biopsy proven acute rejection (tBPAR) with a rejection activity index (RAI) according to Banff classification \>3, graft loss or death at 6 months. Biopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted. The graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.

    Time frame: At week 12 and week 24

  2. Number of Patients With Treated or Not Treated Biopsy Proven Acute Rejection (BPAR)

    Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy.

    Time frame: at 12 week and 24 week

  3. Number of Patients Reported With Different Categories of Severity of BPAR According to Banff Classification

    Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy. The severity of BPAR was categorized as : Mild (Banff grade I, RAI = 4 and 5) Moderate (Banff grade II, RAI = 6 and 7) Severe (Banff grade III, RAI = 8 and 9) Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted.

    Time frame: at 12 week and 24 week

  4. Number of Patients With Treated or Untreated BPAR With RAI Score Greater Than 3

    Biopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted. The patients with treated or untreated BPAR having RAI score \> 3 were reported in this end point.

    Time frame: At 24 weeks

  5. Number of Patients With Death or Graft Loss

    The graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.

    Time frame: at week 24

  6. Change From Baseline (Randomization) in Serum Creatinine

    Change in serum creatinine concentrations from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function. Baseline was Day 28 visit.

    Time frame: Baseline, Week 24

  7. Change From Baseline (Randomization) in Urine Protein/Creatinine Ratio

    Change in urine protein/creatinine ratio from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function. Baseline was Day 28 visit.

    Time frame: Baseline, week 24

  8. Change From Baseline (Randomization) in Creatinine Clearance Estimated Using the Adjusted Cockcroft-Gault Formula

    Creatinine clearance by the Cockcroft-Gault formula is computed in mL/min/1.73m\^2 from the creatinine clearance in mL/min by multiplying it by 1.73 and dividing it by the body surface area Baseline was Day 28 visit.

    Time frame: Baseline, Week 24

  9. Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by Abbreviated Modification of Diet in Renal Disease (MDRD) Formula

    Change in glomerular filtration rate was calculated using the MDRD abbreviated formula. GFR in mL/min/1.73m\^2 for men of non-black ethnicity: 186 \* \[C/88\]\^-1.154 \* \[A\]\^-0.023\*G\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.

    Time frame: Baseline, Week 24

  10. Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by CKD-EPI Formula

    GFR estimated by using the Chronic kidney disease- epidemiology (CKD-EPI) formula: eGFR (mL/min/1.73m\^2) = 141 \* min(C/K,1)\^ α \* max(C/K,1)\^-1.209 \* 0.993\^A \* 1.1018 (if male) \* 1.159 (if black) where C = serum creatinine (in mg/dL) ; A = Age (in years); K = 0.7 for women and 0.9 for men; α = -0.329 for women and -0.411 for men. Baseline was Day 28 visit.

    Time frame: Baseline, Week 24

  11. Number of Patients in Different Stages of Chronic Kidney Diseases According to the K/DOQI Classification System

    Kidney disease outcomes quality initiative (K/DOQI) classification is based on glomerular filtration rate (GFR), abbreviated MDRD formula (mL/min/1.73m\^2) : Stage 1 : GFR \>= 90; Stage 2 = GFR was between 60-89; Stage 3 = GFR was between 30-59 ; Stage 4 = GFR was between 15-29; Stage 5 = GFR was \< 15 (or dialysis)

    Time frame: At Week 24

  12. Number of Patients With Any Adverse Events, Serious Adverse Events, Death and Premature Discontinuation

    Baseline was Day 28 visit. This endpoint reports patients with total adverse events (any), serious adverse events, death and premature discontinuation.

    Time frame: Baseline to 24 weeks

07

Results

Posted Apr 27, 2016

Participant flow

Participant flow — Overall Study
MilestoneTacrolimusEverolimus (RAD001)
Started9593
Safety set of population9490
Intent to treat population9390
Completed8871
Not completed722
Withdrew: Death11
Withdrew: Administrative problem11
Withdrew: Protocol violation03
Withdrew: Adverse event316
Withdrew: Graft loss10
Withdrew: Unsatisfactory therapeutic effect01
Withdrew: Abnormal laboratory values10

Outcome measures

PrimaryChange From Baseline (Randomization) in Renal Function

Change in renal function was measured by change in glomerular filtration rate (GFR). GFR calculated using the abbreviated modification of diet in renal disease (aMDRD) formula. GFR in mL/min/1.73m\^2 for men of non-black ethnicity: 186 \* \[C/88\]\^-1.154 \* \[A\]\^-0.023\*G\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mL/min/1.73m^2
Change From Baseline (Randomization) in Renal Function
mL/min/1.73m^2TacrolimusEverolimus (RAD001)
Change From Baseline (Randomization) in Renal Function-13.29 ± 2.751.05 ± 2.81
Statistical analysis
  • Tacrolimus vs Everolimus (RAD001) · ANCOVA · p = <0.0001 · Mean difference (net): -14.34 · 95% CI -21.34 to -7.34
SecondaryNumber of Patients With Treatment Failures

Incidence of treatment failures, assessed with composite criterion including treated biopsy proven acute rejection (tBPAR) with a rejection activity index (RAI) according to Banff classification \>3, graft loss or death at 6 months. Biopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted. The graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.

Time frame:
At week 12 and week 24
Reported as:
Number · Patients
Number of Patients With Treatment Failures
PatientsTacrolimusEverolimus (RAD001)
week 12, Treatment failures - NO9188
week 12, Treatment failures - YES22
week 24, Treatment failures - NO8981
week 24, Treatment failures - YES49
SecondaryNumber of Patients With Treated or Not Treated Biopsy Proven Acute Rejection (BPAR)

Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy.

Time frame:
at 12 week and 24 week
Reported as:
Number · Patients
Number of Patients With Treated or Not Treated Biopsy Proven Acute Rejection (BPAR)
PatientsTacrolimusEverolimus (RAD001)
Week 12, Treated BPAR22
Week 12, Not treated BPAR00
Week 24, Treated BPAR28
Week 24, Not Treated BPAR01
SecondaryNumber of Patients Reported With Different Categories of Severity of BPAR According to Banff Classification

Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy. The severity of BPAR was categorized as : Mild (Banff grade I, RAI = 4 and 5) Moderate (Banff grade II, RAI = 6 and 7) Severe (Banff grade III, RAI = 8 and 9) Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted.

Time frame:
at 12 week and 24 week
Reported as:
Number · Patients
Number of Patients Reported With Different Categories of Severity of BPAR According to Banff Classification
PatientsTacrolimusEverolimus (RAD001)
Week 12: Mild11
Week 12: Moderate11
Week 12: Severe00
Week 24: Mild15
Week 24: Moderate13
Week 24: Sever00
SecondaryNumber of Patients With Treated or Untreated BPAR With RAI Score Greater Than 3

Biopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted. The patients with treated or untreated BPAR having RAI score \> 3 were reported in this end point.

Time frame:
At 24 weeks
Reported as:
Number · Patients
Number of Patients With Treated or Untreated BPAR With RAI Score Greater Than 3
PatientsTacrolimusEverolimus (RAD001)
Not Treated BPAR: RAI score >300
Not Treated BPAR: Missing RAI score01
Treated BPAR: RAI score >328
SecondaryNumber of Patients With Death or Graft Loss

The graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.

Time frame:
at week 24
Reported as:
Number · Patients
Number of Patients With Death or Graft Loss
PatientsTacrolimusEverolimus (RAD001)
Graft Loss10
Death11
SecondaryChange From Baseline (Randomization) in Serum Creatinine

Change in serum creatinine concentrations from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function. Baseline was Day 28 visit.

Time frame:
Baseline, Week 24
Reported as:
Mean · µmol/L
Change From Baseline (Randomization) in Serum Creatinine
µmol/LTacrolimusEverolimus (RAD001)
Change From Baseline (Randomization) in Serum Creatinine7.2 ± 36.0-1.3 ± 38.53
SecondaryChange From Baseline (Randomization) in Urine Protein/Creatinine Ratio

Change in urine protein/creatinine ratio from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function. Baseline was Day 28 visit.

Time frame:
Baseline, week 24
Reported as:
Mean · mg/mmol
Change From Baseline (Randomization) in Urine Protein/Creatinine Ratio
mg/mmolTacrolimusEverolimus (RAD001)
Change From Baseline (Randomization) in Urine Protein/Creatinine Ratio-2.3 ± 27.8921.9 ± 92.00
SecondaryChange From Baseline (Randomization) in Creatinine Clearance Estimated Using the Adjusted Cockcroft-Gault Formula

Creatinine clearance by the Cockcroft-Gault formula is computed in mL/min/1.73m\^2 from the creatinine clearance in mL/min by multiplying it by 1.73 and dividing it by the body surface area Baseline was Day 28 visit.

Time frame:
Baseline, Week 24
Reported as:
Mean · mL/min/1.73m^2
Change From Baseline (Randomization) in Creatinine Clearance Estimated Using the Adjusted Cockcroft-Gault Formula
mL/min/1.73m^2TacrolimusEverolimus (RAD001)
Change From Baseline (Randomization) in Creatinine Clearance Estimated Using the Adjusted Cockcroft-Gault Formula-9.0 ± 30.630.7 ± 25.65
SecondaryChange From Baseline (Randomization) in Glomerular Filtration Rate Estimated by Abbreviated Modification of Diet in Renal Disease (MDRD) Formula

Change in glomerular filtration rate was calculated using the MDRD abbreviated formula. GFR in mL/min/1.73m\^2 for men of non-black ethnicity: 186 \* \[C/88\]\^-1.154 \* \[A\]\^-0.023\*G\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.

Time frame:
Baseline, Week 24
Reported as:
Mean · mL/min/1.73m^2
Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by Abbreviated Modification of Diet in Renal Disease (MDRD) Formula
mL/min/1.73m^2TacrolimusEverolimus (RAD001)
Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by Abbreviated Modification of Diet in Renal Disease (MDRD) Formula-11.8 ± 34.010.1 ± 32.59
SecondaryChange From Baseline (Randomization) in Glomerular Filtration Rate Estimated by CKD-EPI Formula

GFR estimated by using the Chronic kidney disease- epidemiology (CKD-EPI) formula: eGFR (mL/min/1.73m\^2) = 141 \* min(C/K,1)\^ α \* max(C/K,1)\^-1.209 \* 0.993\^A \* 1.1018 (if male) \* 1.159 (if black) where C = serum creatinine (in mg/dL) ; A = Age (in years); K = 0.7 for women and 0.9 for men; α = -0.329 for women and -0.411 for men. Baseline was Day 28 visit.

Time frame:
Baseline, Week 24
Reported as:
Mean · mL/min/1.73m^2
Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by CKD-EPI Formula
mL/min/1.73m^2TacrolimusEverolimus (RAD001)
Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by CKD-EPI Formula-6.9 ± 20.112.4 ± 22.18
SecondaryNumber of Patients in Different Stages of Chronic Kidney Diseases According to the K/DOQI Classification System

Kidney disease outcomes quality initiative (K/DOQI) classification is based on glomerular filtration rate (GFR), abbreviated MDRD formula (mL/min/1.73m\^2) : Stage 1 : GFR \>= 90; Stage 2 = GFR was between 60-89; Stage 3 = GFR was between 30-59 ; Stage 4 = GFR was between 15-29; Stage 5 = GFR was \< 15 (or dialysis)

Time frame:
At Week 24
Reported as:
Number · Patients
Number of Patients in Different Stages of Chronic Kidney Diseases According to the K/DOQI Classification System
PatientsTacrolimusEverolimus (RAD001)
Stage 124 ± 27.8941 ± 92.00
Stage 23429
Stage 3284
Stage 400
Stage 500
SecondaryNumber of Patients With Any Adverse Events, Serious Adverse Events, Death and Premature Discontinuation

Baseline was Day 28 visit. This endpoint reports patients with total adverse events (any), serious adverse events, death and premature discontinuation.

Time frame:
Baseline to 24 weeks
Reported as:
Number · Patients
Number of Patients With Any Adverse Events, Serious Adverse Events, Death and Premature Discontinuation
PatientsTacrolimusEverolimus (RAD001)
Any Adverse events8581
Serious Adverse events2842
Death12
At least one AE led to premature discontinuation418

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tacrolimus—28/94 (29.8%)68/94 (72.3%)
Everolimus (RAD001)—42/90 (46.7%)64/90 (71.1%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventTacrolimusEverolimus (RAD001)
Liver transplant rejectionImmune system disorders3/945/90
SepsisInfections and infestations0/945/90
Biliary anastomosis complicationInjury, poisoning and procedural complications4/945/90
DiarrhoeaGastrointestinal disorders4/941/90
Renal failureRenal and urinary disorders4/943/90
PancytopeniaBlood and lymphatic system disorders0/942/90
General physical health deteriorationGeneral disorders1/942/90
Hepatocellular injuryHepatobiliary disorders0/942/90
Transplant rejectionImmune system disorders0/942/90
Back painMusculoskeletal and connective tissue disorders0/942/90
Most frequent other events
Showing 10 of 19
Most frequent other events
EventTacrolimusEverolimus (RAD001)
CholestasisHepatobiliary disorders12/9424/90
Hepatocellular injuryHepatobiliary disorders4/9416/90
DiarrhoeaGastrointestinal disorders16/946/90
NeutropeniaBlood and lymphatic system disorders14/949/90
AnaemiaBlood and lymphatic system disorders7/9412/90
HypertensionVascular disorders12/947/90
HypokalaemiaMetabolism and nutrition disorders2/9411/90
Renal failureRenal and urinary disorders11/943/90
LeukopeniaBlood and lymphatic system disorders8/9410/90
ThrombocytopeniaBlood and lymphatic system disorders10/948/90

Baseline characteristics

Randomized population

Age, Continuous
Age, Continuous(Years)TacrolimusEverolimus (RAD001)Total
Mean55.5 ± 8.2456.5 ± 8.5956.0 ± 8.41
Sex: Female, Male
Sex: Female, Male(Participants)TacrolimusEverolimus (RAD001)Total
Female141428
Male8179160
08

Study locations

14 sites
  • Novartis Investigative Site
    Besancon cedex, 25030, France
  • Novartis Investigative Site
    Bordeaux Cedex, 33076, France
  • Novartis Investigative Site
    Chambray les Tours, 37044, France
  • Novartis Investigative Site
    Clichy, 92110, France
  • Novartis Investigative Site
    Creteil, 94010, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Marseille, 13385, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Paris Cedex 13, 75651, France
  • Novartis Investigative Site
    Rennes Cedex, 35033, France
  • Novartis Investigative Site
    Toulouse Cedex 4, 31054, France
  • Novartis Investigative Site
    Villejuif, 94800, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2012
First posted
Jun 21, 2012
Start
Dec 2012
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Apr 27, 2016
Last update
Apr 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01625377
Responsible party
Sponsor
First posted
Jun 21, 2012
Start date
Dec 2012
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Apr 27, 2016
Last update
Apr 27, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion